Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD45 Antibody (MEM-28), FITC, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB11081719
Description
CD45 Monoclonal specifically detects CD45 in Human, Mouse, Equine (Negative) samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry-Paraffin.Specifications
CD45 | |
Monoclonal | |
FITC | |
B220, CD45 antigen, CD45R, EC 3.1.3.48, L-CA, LY5, protein tyrosine phosphatase, receptor type, C, receptor-type tyrosine-protein phosphatase C, T200 glycoprotein, T200 leukocyte common antigen, T200receptor type, c polypeptide | |
Mouse | |
220 kDa | |
100 Tests | |
Adaptive Immunity, Cell Biology, Cellular Markers, Cytokine Research, Hematopoietic Stem Cell Markers, Immunology, Innate Immunity, Mesenchymal Stem Cell Markers, Microglia Markers, Neuronal Cell Markers, Neuroscience, Signal Transduction, Stem Cell Markers | |
5788 | |
Human, Mouse | |
Purified |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Immunohistochemistry (Paraffin) | |
MEM-28 | |
Western Blot 1:100-1:2000, Flow Cytometry 20 ul reagent 100 ul of whole blood or 10^6 cells in a suspension, Immunohistochemistry 1:10-1:500, Immunoprecipitation 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500 | |
PTPRC | |
Human thymocytes and T lymphocytes. | |
Size Exclusion Chromatography | |
RUO | |
Primary | |
The antibody MEM-28 reacts with all alternative forms of human CD45 antigen (Leukocyte Common Antigen), a 180-220 kDa single chain type I transmembrane protein expressed at high level on all cells of hematopoietic origin, except erythrocytes and platelets. HLDA III; WS Code NL 833a | |
Store at 4C in the dark. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction